Advertisement
Australia markets open in 5 hours 34 minutes
  • ALL ORDS

    7,937.90
    +35.90 (+0.45%)
     
  • AUD/USD

    0.6490
    +0.0039 (+0.61%)
     
  • ASX 200

    7,683.50
    +34.30 (+0.45%)
     
  • OIL

    83.36
    +1.46 (+1.78%)
     
  • GOLD

    2,342.00
    -4.40 (-0.19%)
     
  • Bitcoin AUD

    102,976.72
    +359.94 (+0.35%)
     
  • CMC Crypto 200

    1,437.09
    +22.33 (+1.58%)
     

Read This Before Selling Jack Nathan Medical Corp. (CVE:JNH) Shares

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we'll take a look at whether insiders have been buying or selling shares in Jack Nathan Medical Corp. (CVE:JNH).

Do Insider Transactions Matter?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, such insiders must disclose their trading activities, and not trade on inside information.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But it is perfectly logical to keep tabs on what insiders are doing. For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year'.

ADVERTISEMENT

Check out our latest analysis for Jack Nathan Medical

The Last 12 Months Of Insider Transactions At Jack Nathan Medical

While no particular insider transaction stood out, we can still look at the overall trading.

In the last twelve months insiders purchased 281.50k shares for CA$243k. But they sold 25.90k shares for CA$26k. Overall, Jack Nathan Medical insiders were net buyers during the last year. The average buy price was around CA$0.86. This is nice to see since it implies that insiders might see value around current prices (around CA$0.49). You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

Jack Nathan Medical is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does Jack Nathan Medical Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Jack Nathan Medical insiders own about CA$22m worth of shares (which is 55% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Do The Jack Nathan Medical Insider Transactions Indicate?

The fact that there have been no Jack Nathan Medical insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. With high insider ownership and encouraging transactions, it seems like Jack Nathan Medical insiders think the business has merit. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For example - Jack Nathan Medical has 3 warning signs we think you should be aware of.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.